Cancer Research6d
Encorafenib Granted Accelerated Approval for Colon Cancer
The FDA granted accelerated approval to encorafenib (Braftovi; Array BioPharma/Pfizer), a BRAF inhibitor, in combination with the anti-EGFR mAb cetuximab (Erbitux; Eli Lilly) and the chemotherapy ...
Cancer Research6d
ROS1 TKI Approved in China
Innovent Biologics’ ROS1 tyrosine kinase inhibitor (TKI) taletrectinib adipate (Dovbleron) was approved by the National Medical Products Administration, the Chinese equivalent of the FDA, for patients ...
Cancer Research6d
ALK TKI Earns FDA Approval
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The decision was ...
Cancer Research6d
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...